Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Weiser

Showing results (131-140 of 176) with videos related to

Pageof 18
Sort By:
Archives of General Psychiatry|December 7, 2005
Elaboration on premorbid intellectual performance in schizophrenia: premorbid intellectual decline and risk for schizophreniaAbraham Reichenberg, Mark Weiser, Michael A Rapp, et al.
Harefuah|January 27, 2005
[Sex reassignment surgery]Haim Kaplan, Eran Bar-Meir, Dalia Gilboa, et al.
Schizophrenia Research|April 22, 2006
Premorbid intra-individual variability in intellectual performance and risk for schizophrenia: a population-based studyAbraham Reichenberg, Mark Weiser, Michael A Rapp, et al.
Journal of Clinical Psychopharmacology|June 4, 2010
Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatmentHarrison G Pope, Revital Amiaz, Brian P Brennan, et al.
Schizophrenia Bulletin Open|November 6, 2024
Intranasal Oxytocin Combined With Social Skills Training for Schizophrenia: An Add-on Randomized Controlled TrialLiron Saporta-Wiesel, Ruth Feldman, Linda Levi, et al.
The American Journal of Psychiatry|July 14, 2021
Differences in Antipsychotic Treatment Discontinuation Among Veterans With Schizophrenia in the U.S. Department of Veterans AffairsMark Weiser, John M Davis, Clayton H Brown, et al.
CNS Drugs|September 11, 2025
Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized TrialMatin Mortazavi, Zahra Aminifarsani, Inge Winter-van Rossum, et al.
Schizophrenia Bulletin|March 31, 2023
Cannabis Use and Symptomatic Relapse in First Episode Schizophrenia: Trigger or Consequence? Data From the OPTIMISE StudyLinda Levi, Mor Bar-Haim, Inge Winter-van Rossum, et al.
Bipolar Disorders|June 13, 2017
A randomized, double-blind, placebo- and risperidone-controlled study on valnoctamide for acute maniaMark Weiser, Linda Levi, Stephen Z Levine, et al.
Archives of General Psychiatry|September 6, 2006
Advancing paternal age and autismAbraham Reichenberg, Raz Gross, Mark Weiser, et al.
Pageof 18

Showing results (131-140 of 176) with videos related to

Sort By:
Pageof 18
Archives of General Psychiatry|December 7, 2005
Elaboration on premorbid intellectual performance in schizophrenia: premorbid intellectual decline and risk for schizophreniaAbraham Reichenberg, Mark Weiser, Michael A Rapp, et al.
Harefuah|January 27, 2005
[Sex reassignment surgery]Haim Kaplan, Eran Bar-Meir, Dalia Gilboa, et al.
Schizophrenia Research|April 22, 2006
Premorbid intra-individual variability in intellectual performance and risk for schizophrenia: a population-based studyAbraham Reichenberg, Mark Weiser, Michael A Rapp, et al.
Journal of Clinical Psychopharmacology|June 4, 2010
Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatmentHarrison G Pope, Revital Amiaz, Brian P Brennan, et al.
Schizophrenia Bulletin Open|November 6, 2024
Intranasal Oxytocin Combined With Social Skills Training for Schizophrenia: An Add-on Randomized Controlled TrialLiron Saporta-Wiesel, Ruth Feldman, Linda Levi, et al.
The American Journal of Psychiatry|July 14, 2021
Differences in Antipsychotic Treatment Discontinuation Among Veterans With Schizophrenia in the U.S. Department of Veterans AffairsMark Weiser, John M Davis, Clayton H Brown, et al.
CNS Drugs|September 11, 2025
Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized TrialMatin Mortazavi, Zahra Aminifarsani, Inge Winter-van Rossum, et al.
Schizophrenia Bulletin|March 31, 2023
Cannabis Use and Symptomatic Relapse in First Episode Schizophrenia: Trigger or Consequence? Data From the OPTIMISE StudyLinda Levi, Mor Bar-Haim, Inge Winter-van Rossum, et al.
Bipolar Disorders|June 13, 2017
A randomized, double-blind, placebo- and risperidone-controlled study on valnoctamide for acute maniaMark Weiser, Linda Levi, Stephen Z Levine, et al.
Archives of General Psychiatry|September 6, 2006
Advancing paternal age and autismAbraham Reichenberg, Raz Gross, Mark Weiser, et al.
Pageof 18